We are live on ! Find out more

Stevanato

STVN

Market cap $5.53B

20.24 USD

+0.81

4.17%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

20.24

0.00

0%

1 day

4.17%

5 days

4.01%

1 month

-4.53%

3 months

-0.83%

6 months

24.48%

Year to date

-1.65%

1 year

-21.55%

5 years

-21.15%

10 years

2.9%

About: Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

Employees: 5,795

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 64.3%

Negative 7.1%

Conestoga Small Cap Composite Q3 2026 Portfolio Activity

The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Small Cap Composite bottom 5 laggards include Mercury Systems, AAON, RBC Bearings, SPX Technologies and UL Solutions.

Conestoga Small Cap Composite Q3 2026 Portfolio Activity

Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapie.

Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection

Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.

Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update

Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, November 3, 2026, to di.

Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Baron Global Durable Advantage ETF Q2 2026 Portfolio Activity

During the second quarter, we initiated three new positions: a leading software and semiconductor company, Broadcom, Samsung Electronics, and INNIO. We took advantage of inflows and market volatility to add to 36 existing positions. We also exited three investments – Indutrade, HDFC Bank, and Wix – reallocating to names in which we saw a more attractive risk-reward profile.

Baron Global Durable Advantage ETF Q2 2026 Portfolio Activity

Stevanato Group to Participate in Two Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Confere.

Stevanato Group to Participate in Two Upcoming Investor Conferences

Stevanato Group: Alina Validates The Container-To-Device Flywheel

Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, validated by commercial adoption of its Alina injector. High-value solutions now drive 45% of revenue, growing 16% year-over-year, with recent capacity investments in Fishers and Latina expected to boost operating leverage and margin expansion. STVN is shifting its portfolio toward premium, integrated offerings, divesting low-margin assets like Balda and focusing on durable, higher-margin customer relationships.

Stevanato Group: Alina Validates The Container-To-Device Flywheel

Stevanato Group Q2 Earnings Call Highlights

Stevanato Group NYSE: STVN reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its full-year outlook to reflect the divestiture of its California-based Balda C. Brewer subsidiary.

Stevanato Group Q2 Earnings Call Highlights

Zacks Investment Research

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

See News Rankings

Price charts implemented using Lightweight Charts™